To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
April 15, 2018
Primary Completion Date
December 6, 2019
Study Completion Date
December 6, 2019
Conditions
Healthy
Interventions
DRUG
K0706
Study
DRUG
K0706
Study
DRUG
K0706
Study
Trial Locations (1)
91206
SPARC Site 1, Glendale
All Listed Sponsors
lead
Sun Pharma Advanced Research Company Limited
INDUSTRY
NCT03445338 - To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers | Biotech Hunter | Biotech Hunter